In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells

被引：0
|
作者：
Rita Nahta
Francisco J. Esteva
机构：
[1] The University of Texas M. D. Anderson Cancer Center,Department of Breast Medical Oncology
[2] The University of Texas M. D. Anderson Cancer Center,Department of Molecular and Cellular Oncology
来源：
Cancer Chemotherapy and Pharmacology | 2004年 / 53卷
关键词：
Apoptosis; Dose-response; Herceptin; Resistance; SKBR3;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：186 / 190
页数：4
相关论文
共 50 条
  • [41] Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies
    Szoor, Arpad
    Toth, Gabor
    Zsebik, Barbara
    Szabo, Viktoria
    Eshhar, Zelig
    Abken, Hinrich
    Vereb, Gyorgy
    CANCER LETTERS, 2020, 484 : 1 - 8
  • [42] In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells
    Tuba Ozbay
    Donald L. Durden
    Tongrui Liu
    Ruth M. O’Regan
    Rita Nahta
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 697 - 706
  • [43] In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells
    Ozbay, Tuba
    Durden, Donald L.
    Liu, Tongrui
    O'Regan, Ruth M.
    Nahta, Rita
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 697 - 706
  • [44] A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer
    Nam, Seungyoon
    Chang, Hae Ryung
    Jung, Hae Rim
    Gim, Youme
    Kim, Nam Youl
    Grailhe, Regis
    Seo, Haeng Ran
    Park, Hee Seo
    Balch, Curt
    Lee, Jinhyuk
    Park, Inhae
    Jung, So Youn
    Jeong, Kyung-Chae
    Powis, Garth
    Liang, Han
    Lee, Eun Sook
    Ro, Jungsil
    Kim, Yon Hui
    CANCER LETTERS, 2015, 356 (02) : 880 - 890
  • [45] Recent Insights into the Development of Preclinical Trastuzumab-Resistant HER2+Breast Cancer Models
    Gonzalez-Alonso, Paula
    Cristobal, Ion
    Zazo, Sandra
    Martin-Aparicio, Ester
    Chamizo, Cristina
    Madoz-Gurpide, Juan
    Rovira, Ana
    Eroles, Pilar
    Lluch, Ana
    Albanell, Joan
    Rojo, Federico
    CURRENT MEDICINAL CHEMISTRY, 2018, 25 (17) : 1976 - 1998
  • [46] Safety analysis of BOLERO-3: A phase 3 trial of daily everolimus (EVE) vs placebo (PBO), both with weekly trastuzumab (TRAS) and vinorelbine in trastuzumab-resistant, advanced breast cancer
    Jerusalem, G.
    Masuda, N.
    Andre, F.
    Fein, L.
    Fasolo, A.
    O'Regan, R.
    Wilks, S.
    Isaacs, C.
    Zhang, Y.
    Taran, T.
    Toi, M.
    CANCER RESEARCH, 2013, 73
  • [47] Selenium inhibits growth of trastuzumab-resistant human breast cancer cells via downregulation of Akt and beclin-1
    Woo, Joohyun
    Kim, Jong Bin
    Cho, Taeeun
    Yoo, Eun Hye
    Moon, Byung-In
    Kwon, Hyungju
    Lim, Woosung
    PLOS ONE, 2021, 16 (09):
  • [48] Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer
    Yu, Chaoran
    Xue, Pei
    Zhang, Luyang
    Pan, Ruijun
    Cai, Zhenhao
    He, Zirui
    Sun, Jing
    Zheng, Minhua
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2018, 16
  • [49] Hedgehog Pathway Is a Regulator of Stemness in HER2-Positive Trastuzumab-Resistant Breast Cancer
    Er, Idris
    Er, Asiye Busra Boz
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (22)
  • [50] Generation, characterization, and maintenance of trastuzumab-resistant HER2+breast cancer cell lines
    Zazo, Sandra
    Gonzalez-Alonso, Paula
    Martin-Aparicio, Ester
    Chamizo, Cristina
    Cristobal, Ion
    Arpi, Oriol
    Rovira, Ana
    Albanell, Joan
    Eroles, Pilar
    Lluch, Ana
    Madoz-Gurpide, Juan
    Rojo, Federico
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (11): : 2661 - +
12345